Introduction
The interferon (IFN) group of cytokines regulates antitumor, antiviral and immune responses. Clinical studies show the efficacy of IFN in the treatment of different cancers, such as chronic myelogenous leukemia, Kaposi's sarcoma, lymphomas, hairy cell leukemia, melanoma and renal cell carcinoma (Jonasch and Haluska, 2001 ). More strikingly, the anti-proliferative effects of IFN are augmented when combined with retinoids, a class of vitamin A metabolites and synthetic homologues. For example, co-treatment of MCF-7 breast cancer cells with retinoic acid and IFN-b leads to synergistic upregulation of a set of pro-apoptotic gene products (TRAIL, DR3, FAS, etc.) (Ma et al., 2001) and suppression of tumor growth through apoptosis (Kolla et al., 1996; Lindner et al., 1997) . On the basis of these observations, we hypothesized that cell death by the co-treatment of retinoic acid and IFN-b is induced through stimulation of a group of genes at the molecular level. To identify these apoptotic genes, we applied a genetic method, and isolated a novel group of genes and were collectively named Genes associated with RetinoidInterferon-induced Mortality (GRIMs) (Angell et al., 2000) . Knockdown of any GRIM ablated IFN-b/ retinoic acid-induced cell death response. One such gene product, GRIM-19, caused apoptosis upon over expression. However, cells expressing moderate levels of GRIM-19 grew significantly slower than the corresponding vector-only controls. Subsequently, GRIM-19 was shown to been a component of mitochondrial electron transport system complex I (Fearnley et al., 2001) . The first direct evidence to implicate GRIM-19 as a potential tumor suppressor was illustrated by direct suppression of the transcriptional activity of STAT3 (Lufei et al., 2003; Zhang et al., 2003) . In addition, the blockade of GRIM-19 by viral encoded products (Seo et al., 2002) , mutations in thyroid tumors (Maximo et al., 2005) , and loss of expression in renal cell carcinoma (Alchanati et al., 2006) and in some prostate cancers (Zhang et al., 2008) indicates a typical tumor suppressor-like character for GRIM-19. Recently, we have shown that the anti-tumor effect of GRIM-19 was exerted at multiple levels on oncogenic v-Src through inhibition of cellular transformation, injury-induced and mitogen-driven migration of cells and in vivo tumor formation (Kalakonda et al., 2007a) .
v-Src expression controls several cellular activities, including cell morphology, adhesion, motility, invasion, etc. (Martin, 2001 ) by interacting with the plasma membrane and inducing tyrosine phosphorylation of membrane-associated and other cellular proteins (Frame et al., 2002) . By associating with cytoskeleton, v-Src causes changes in cell morphology and structure.
For example, cells transformed by v-Src convert from a well-spread shape into an extremely rounded shape, which is a characteristic of high motility and invasiveness of transformed cells. Most of these changes were associated with a reorganization of the cytoskeleton, including loss of stress fibers, adhesion plaques and formation of podosomes (dot-like structures rich with bundled F-actin) (Hakak et al., 2000) . One of the most important substrates of v-Src is cortactin, a filamentous actin-bundling protein (Wu and Parsons, 1993) , which serves as a scaffold protein linking the v-Src signaling pathway to the organization of cytoskeleton. For example, tyrosine phosphorylation of cortactin by v-Src is essential for formation of podosomes. The proteolytic activity of podosomes causes cellular matrix degradation, leading to invasive capability of transformed cells. Tyrosyl phosphorylation of cortactin by v-Src occurs in a progressive manner (Head et al., 2003) . Studies have shown that phosphorylation of cortactin by v-Src reduced the affinity of cortactin for actin and its ability to cross-link actin filaments (Huang et al., 1997) . Depletion of cortactin leads to a specific loss of podosomes, and re-expression of cortactin mutants lacking phospho-accepting residues (Y 421 , Y 466 and Y
482
) does not restore podosome formation (Tehrani et al., 2006) . This attenuating effect of GRIM-19 on v-Src-induced cell migration led us to explore the mechanism by which GRIM-19 suppresses cancer cell metastasis and whether tumor-associated GRIM-19 mutations affect the function in this aspect. In this study, we show that wild-type GRIM-19 can reverse v-Src-induced cytoskeleton remodeling, especially formation of podosome. In addition, we show that the N terminus of GRIM-19 is required for suppressing v-Src-induced cell motility. Experimental and tumor-associated mutations in the N-terminal region of GRIM-19 significantly lost their ability to suppress v-Src-induced cell cytoskeleton restructuring and cortactin phosphorylation, compared with wild-type GRIM-19.
Results
GRIM-19 suppresses v-Src-induced cellular morphology change and podosome formation Our earlier study showed that GRIM-19 inhibits v-Srcinduced transformation at multiple levels, including cell motility. Cells transformed by v-Src go through a series of morphological and cytoskeletal changes, which permits the loss of cell adhesion and a potential for motility. Therefore, we first studied whether GRIM-19 affected v-Src-induced morphological change and cytoskeletal restructuring. As most cancer cells possess multiple oncogenic changes, we used a non-oncogenic rat fibroblast line 3Y1, where the introduction of a single oncogene such as v-Src is sufficient to cause cellular transformation. Cells transfected with expression vector coding v-Src and control vector were used for this study. After infecting these cells with lentivirus coding for GRIM-19, cells were selected for 5 days with puromycin to eliminate uninfected cells (usually o5% under these conditions). In the presence of v-Src, around 70% of cells appeared rounded and ready to detach from the substratum compared with the controls that were well-spread in shape, indicative of strong adherence ( Figure 1a ). This rounded appearance of v-Srctransformed cells returned to the morphology of naive 3Y1 cells upon expression of GRIM-19. However, GRIM-19 expression alone did not cause any morphological change (Figure 1a) . The expressions of exogenous v-Src and GRIM-19 were confirmed by the western blot analysis (Figure 2) .
The cytoskeleton, including actin and tubulin, maintains cell morphology and modulates motility. Therefore, we further examined the effect of GRIM-19 on v-Src-induced cytoskeletal restructuring. As shown in Figure 1b , the expression of v-Src led to the loss of stress fibers and the formation of podosomes, compared with the control cells upon phalloidin staining. The podosomes are structures formed by bundled actin, whose proteolytic activity enables the transformed cells to lose adhesion and enhance motility. Expression of GRIM-19 restored the formation of stress fibers and inhibited the formation of podosomes in v-Src-transformed cells (Figure 1b ). This probably explains the assumption of flat and adherent morphology of v-Src-transformed cells in the presence of GRIM-19. There was no significant change in the tubulin network in the v-Src-transformed cells (Figure 1c) . However, the tubulin staining pattern was more condensed in the v-Src-transformed cells because of the round shape of these cells. Expression of GRIM-19 recovered the tubulin staining pattern similar to that found in control cells. Surprisingly, in the v-Srctransformed cells, there was a slight decrease in the density of detyrosinated tubulin. Although all cells were photographed at the same magnification, the v-srcexpressing cells appear to have a smaller size nucleus. This could be due to an impact of cytoskeletal reorganization on the nucleus.
GRIM-19 reduced the phosphorylation status of cortactin catalyzed by v-Src
The effect of v-Src on actin matrix is mediated by cortactin, an F-actin-bundling protein that localizes to podosomes and lamellipodia. Tyrosyl phosphorylation of cortactin is required for the formation of podosomes, which impart high motility to v-Src-transformed cells. In the next experiment, we examined whether GRIM-19 interfered with v-Src-induced tyrosyl phosphorylation of cortactin. There are three critical tyrosine residues (Y 421 , Y 466 , and Y
482
) located in the prolyl-rich region of cortactin. Sequential phosphorylation of these three residues, in which phosphorylation of Y 421 is required for phosphorylation of the remaining two, occurs in v-Src-transformed cells. Therefore, we performed western blot analyses with Y421-specific antibodies. It can be noted that v-Src induced a robust phosphorylation of cortactin, which was strongly suppressed in the presence of GRIM-19 (Figure 2) . The difference in the tyrosyl phosphorylation was not attributable to a differential loading of proteins in these lanes, as revealed by equivalent levels of total cortactin in these lanes ( Figure 2b, bottom blots) . Surprisingly, GRIM-19 also suppressed the tyrosyl phosphorylation of v-Src. This difference was not because of different levels of exogenous v-Src protein in the cells, as comparable levels of total Src proteins were detected in the presence and absence of GRIM-19 using an Src monoclonal antibody. As expected, the v-Src transfectants had a higher (B2-fold) level of total Src protein than that of the empty vector-expressing cells. Thus, GRIM-19 inhibits the activity of v-Src by reducing the tyrosyl phosphorylation status of cortactin. However, we were unable to detect an interaction between either v-Src and GRIM-19 or cortactin and GRIM-19 upon immunoprecipitation analysis (data not shown).
STAT3 did not influence the suppression of v-Src-induced podosome formation
We and others have shown earlier that STAT3 is inhibited by GRIM-19. Therefore, we next examined whether v-Src-induced podosome formation required STAT3 because of the following observations: (1) STAT3 is a prominent substrate of v-Src and phosphorylation of STAT3 plays a very important role in v-Src-induced transformation (Bromberg et al., 1998) ; (2) GRIM-19 inhibits STAT3-induced gene expression as well as cell growth ; and (3) STAT3 has been suggested to regulate the assembly of cytoskeleton (Ng et al., 2006) . Therefore, we knocked down the endogenous STAT3 using lentiviral vectors coding for STAT3 shRNA. The specific loss of STAT3 protein expression was verified by the western blot analysis of cellular lysates (Supplementary Figure S1A) . STAT3 shRNA significantly promoted the loss of endogenous STAT3 compared with the controls. However, knockdown of STAT3 neither affected podosome formation in the v-Src-transformed 3Y1 cells nor reversed the inhibition of podosome formation by GRIM-19 (Supplementary Figure S1B) . These results suggest that the inhibitory effect of GRIM-19 on v-Srcinduced podosome formation occurs through a STAT3-independent pathway. Further, we checked the effect of STAT3 knockdown on the microtubule (MT) network. As shown in Supplementary Figure S1C , knockdown of STAT3 severely impaired the MT network, as demonstrated by a-tubulin and detyrosinated tubulin staining in both v-Src and v-Src/GRIM-19-expressing cells. Thus, the loss of STAT3 expression severely impaired only the MT network and does not seem to affect The N terminus of GRIM-19 is necessary for suppressing v-Src-induced podosome formation To determine the functional domains required for the GRIM-19 protein to suppress the v-Src-induced effects, we used a deletion mutant lacking the N-terminal 17 amino acids and compared its effects on the v-Srcinduced podosome formation with wild-type GRIM-19. Overall 80% of the v-Src-expressing cells possessed podosomes, which was robustly suppressed by wild-type GRIM-19. Unlike wild-type GRIM-19, the ND17 mutant lost its ability to suppress 'dot-like' podosome formation (Figures 3a and b) . To further narrowly define the residues critical for the GRIM-19-mediated suppression of podosome formation, we searched for conserved motifs in the N terminus of GRIM-19 protein. These studies identified a small predicted motif within the N terminus of GRIM-19, similar to the one found in some ECHO-and human influenza viral proteins. It can be noted that four amino acids located between 8 and 11 position were conserved among these proteins. Therefore, we individually mutated amino acids 8-11 and constructed lentiviral expression vectors. The lentiviral particles coding for mutant GRIM-19 (Q8A, D9A, M10A and P11A) were used to infect v-Src-transformed cells and stable lines were generated. Compared with wild-type GRIM-19, the mutants were less effective in inhibiting the formation of podosomes, although to a varying extent (Figures 3a and b) . In particular, mutations of the ninth residue of GRIM-19 (D9A) almost totally lost the inhibitory effect on v-Srcinduced podosome formation. The differential activities Representative western blot profiles of total cellular lysates probed with the indicated antibodies and signals generated using enhanced chemiluminescence (ECL). Typically, duplicate gels were run in parallel, and after transfer, the membrane was cut horizontally aided by protein molecular weight marker front (pre-stained) and incubated with the following antibodies separately: (a) cortactin (1:2000) or phosphorylated cortactin (1:1000), (b) Myc-tag (1:1000), (c) Actin (1:2000) and (d) Src (1:1000) or phosphorylated Src (1:1000). In some cases, a membrane was first probed with an antibody that detects the phosphorylated form of the protein (pY 421 cortactin or pY 416 v-Src), then striped and reprobed with an antibody to detect the total protein (cortactin or Src). Figures  S2A and B) .
Tumor-associated GRIM-19 mutations impair the inhibitory effect on v-Src-induced cytoskeletal changes Recently, somatic and germ-line mutations of GRIM-19 were identified in Hu¨rthle cell thyroid tumors. However, the effects of these mutations on GRIM-19 function have not been examined. Therefore, we engineered these mutations into GRIM-19 to generate K5N and R115P constructs (see Supplementary Table S1 ). Lentiviral particles coding for wild type or mutants infected into v-Src-transformed 3Y1 cells to generate stable cell lines. We first investigated podosome formation in these cells using AlexaFluor555-conjugated phalloidin. As shown in Figures 3c and d , v-Src induced the formation of podosomes and altered cellular morphology to a round shape in B80% of cells. As expected, wild-type GRIM-19 inhibited the formation of podosomes in almost all the v-Src-transformed cells and clearly restored stress fibers. In the presence of GRIM-19, most of the v-Srcexpressing cells changed from a round shape to a typical adherent cell shape, like naive 3Y1 cells. The mutants were significantly impaired in their ability to the restore the morphological changes and inhibit podosome formation, compared with wild-type GRIM-19 ( Figures  3c and d) . Quantification of cells showed only 20% of v-Src-transformed cells still contained podosomes in the presence of wild-type GRIM-19, whereas both GRIM-19 mutants were significantly defective in inhibiting podosome formation in v-Src-transformed cells. The K5N and R115P mutants allowed the formation of podosomes by 55 and 46%, respectively (Figure 3d ). Thus, tumor-associated mutations impaired the antiv-Src effect of GRIM-19. As mentioned earlier (see Figure 2) , tyrosyl phosphorylation of cortactin by v-Src is implicated in the formation of podosomes. Therefore, we examined whether GRIM-19 mutants have lost their ability to suppress cortactin phosphorylation. Lysates prepared from cells expressing GRIM-19 mutants were probed for total cortactin and phosphorylated cortactin. GRIM-19 mutants (K5N, R115P, Q8A, D9A, M10A and ND17) were significantly less competent at suppressing v-Src-induced phosphorylation of cortactin (Figures 4a and b) whereas P11A retained its ability to suppress phosphorylation of cortactin, which was in accordance with the ability of P11A in inhibiting podosome formation (see Figure 3a) . Expression of GRIM-19 mutants alone in 3Y1 cells did not affect phosphorylation of cortactin ( Supplementary  Figures S3A and B) . Thus, the ability of GRIM-19 to suppress cortactin phosphorylation directly correlated with the inhibition of v-Src-induced actin filament restructuring and podosome formation. All mutants were expressed to an equivalent level to some extent. Unusually, the D9A mutant ran slower than other mutants. The reason for this anomalous migration is unclear, although there are no other differences in the sequence except for the mutant residue in this construct. 
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In summary, clinical and experimental mutations in the N terminus of GRIM-19 suppressed its ability to inhibit v-Src-induced podosome formation and cortactin phosphorylation.
GRIM-19 mutants fail to suppress v-Src-induced motility
To determine the biological relevance of the above observations, we performed cell motility assays. Confluent monolayers expressing v-Src, GRIM-19 mutants and their combinations were used for this study. A scratch was induced into these monolayers and the sloughed cells were removed. Cell monolayers were fed with growth medium, and the migration of cells into the denuded area was monitored at 4 h. Representative data are shown in Figure 5a . As the wild-type GRIM-19 or mutants alone were no different from vector control (data not shown), we have only shown the effect of GRIM-19 cell motility in this figure. It is clear from this study that v-Src robustly activates cell motility after the injury, as evidenced by the reformation of monolayer. Wild-type GRIM-19 strongly suppressed the v-Srcinduced motility. In contrast, the K5N and ND17 mutants significantly lost their ability to suppress v-Src-induced cell motility. The R115P mutant was slightly stronger at suppressing v-Src-induced motility than K5N and ND17 mutants. Figure 5b shows the quantified view of these data.
Mutants defective in N terminus lost their ability to suppress v-Src-induced metastasis in vivo To study the pathological relevance and biological significance of the above observations in vivo, we performed metastatic assays. Cell lines expressing wildtype GRIM-19, K5N (clinical mutant) and ND17 (experimental mutant) in the presence of v-Src were used for these studies. Cell lines expressing v-Src alone and GRIM-19 alone were used as controls for this study. Athymic nude mice (n ¼ 10) were injected with 50 000 cells per mouse through the tail vein. Mice were then evaluated for the presence of tumor masses in lungs after 7 weeks. As shown in Table 1 , no metastases were found in mice injected with control cells and GRIM-19 or its mutants. In contrast, v-Src-transformed cells formed a significant number of metastases. However, in the presence of wild-type GRIM-19, there were fewer metastases. Although the K5N mutant was effective at suppressing tumor metastases, it was significantly weaker than wild-type GRIM-19. The experimental mutant ND17 significantly lost the anti-v-Src effect and behaved more like v-Src-transformed cells. These data for the first time show the in vivo importance of GRIM-19 mutants to tumor metastasis. Effect of GRIM-19 on v-Src P Sun et al
Discussion
In a recent study, we identified GRIM-19 inhibits v-Srcinduced oncogenic transformation at multiple levels (Kalakonda et al., 2007a) . GRIM-19 not only exerted its inhibitory effect on v-Src-induced gene expression through STAT3 but also significantly suppressed the v-Src-induced invasion and cell motility. In this study, we explored a mechanism by which GRIM-19 suppresses v-Src-induced cell motility through its effects on cytoskeletal remodeling. We mapped the N terminus of GRIM-19 as an important regulator of this process. More importantly, we showed for the first time that tumor-associated mutations cause dysfunction of its anti-oncogenic activity. Underlining the various cellular mechanical process, it is the spatial distribution and dynamic rearrangement of cytoskeleton, which determines cellular fate, including mitosis, invasion, morphological changes and anoikis (Rodriguez et al., 2003) . GRIM-19 rescued the v-Src-induced aberrant cellular morphology, which endows transformed cells with a potential for anchorage-independent expansion. GRIM-19 not only slightly affected the v-Src-induced microtubulin structuring but also, in a large part, suppressed the formation of podosomes. The dot-like podosomes in the transformed cells result from the bundled actin filaments, and its proteolytic activity, involving an MMP (matrix metalloproteinase)-mediated pathway (Monsky et al., 1993) , that degrades extracellular matrix and the basement membrane (Mizutani et al., 2002) . These enable tumor cells to detach from primary sites, intravasate into blood vessels and disseminate to distant organs (Coussens et al., 2002) . Nonetheless, this is not the only mechanism by which GRIM-19 can suppress the proteolytic activity of MMP. We and other groups had shown that the direct association of GRIM-19 with STAT3 leads to the inhibition of STAT3-driven transcription of genes implicated in tumorigenesis, including Bcl-X L , cyclin B1, etc. Kalakonda et al., 2007b) and MMP1 (Itoh et al., 2006) . In this sense, GRIM-19 can regulate upstream events in the MT1-MMP-mediated invasion and metastasis through multiple signaling pathways. Apart from the formation of podosomes, expression of v-Src also disrupted stress fibers and perturbed the polymerization of microtubules (Figures 1b and c) . This may involve the Rho family of small GTPase, RhoA, which regulates both actin and tubulin polymerization (Wittmann and Waterman-Storer, 2001) , and this activity is antagonized by RhoGAP, a prominent downstream substrate of v-Src (Ellis et al., 1990) . Tyrosyl phosphorylation of RhoGAP by v-Src negatively regulates the function of RhoA and downstream factors of RhoA-mediated pathway, the latter leading to the disruption of stress fibers and reduction of tubulin polymerization in v-Src-transformed cells. Expression of GRIM-19 antagonizes the v-Srcinduced aberrant cytoskeletal change, which are implicated in the enhanced motility of transformed cells. Considering links between STAT3 and v-Src; STAT3 and GRIM-19 to the cytoskeletal network, we speculated that STAT3 might be involved in the GRIM-19-mediated suppression of v-Src-induced cytoskeletal restructuring. In contrast to this hypothesis, our results showed that STAT3 was not required for v-Src-induced podosome formation and its loss did not block the inhibitory effect of GRIM-19. Cortactin, an actinassociated protein, is an emerging scaffold protein, which couples v-Src signaling to cytoskeletal remodeling (Wu et al., 1991) . Phosphorylation of cortactin by v-Src and other Src family kinases initiates a sequential cellular dynamic process: (1) neutralizes the crosslinking activity of filamentous actin (Huang et al., 1997) ; (2) enhances the actin assembly in vivo (Tehrani et al., 2007) ; and (3) plays an essential role in the formation of podosome (Tehrani et al., 2006) . Our results show that GRIM-19 dramatically suppressed vSrc-induced tyrosyl phosphorylation of Cortactin. This could be one of the mechanisms that explain the suppressive role of GRIM-19 on v-Src-induced podosome formation.
The pathological relevance of our studies is highlighted by the observations that experimental and tumor-associated mutations resulted in a loss of GRIM-19 effects on v-Src-induced podosome formation and cortactin phosphorylation. One of the clinical mutants falls into the N terminus domain mapped in this study. Our result showed that other residues in GRIM-19 (D9, Q8 and M10) also play a major role in the suppression of podosome formation and cortactin phosphorylation. Whether mutations also occur at these positions of GRIM-19 in primary tumors is unknown at this stage. We will be looking at this issue in our future studies.
Lastly, the biological and pathological significance of our observations were highlighted with the data shown in Figure 5 and Table 1 . Both in vitro and in vivo, GRIM-19 appears to ablate cell motility and metastatic behavior of cells. The clinical mutant (K5N) and the experimental mutant (ND17) were weaker compared with wild-type GRIM-19. These data for the first time show a clinical importance of GRIM-19 mutations to tumor metastases. Whether similar mutations occur in other primary tumors need to be studied in the future. This is one of our top priorities for the future. Athymic nude mice were injected 0.5 Â 10 5 in a volume of 0.1 ml through the tail vein. n ¼ 10 mice/group. Seven weeks later, mice were euthanized and necropsy was performed. Metastases in the lungs of each group were counted. *P>0.001; **P>0.01 with respect to vector controls.
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Materials and methods

Plasmids and reagents
Wild-type and mutants of GRIM-19 were generated using PCR and subsequently cloned into pIRES-Puro2 vector and expressed as C-terminally Myc-tagged proteins. Point mutations, K5N and R115P, were originally reported in thyroid tumors (Maximo et al., 2005) and were reconstructed using PCR-directed mutagenesis. The primers used for generation of mutants are presented in Supplementary  Table S1 . Sequence-verified constructs were used to generate lentiviral particles, which were used in all experiments. The mammalian expression vectors for v-Src and lentiviral STAT3 shRNA vector, and their controls have been described (Kalakonda et al., 2007a 
Lentiviral particles
For generating viral particles, GRIM-19 inserts were cloned into the XhoI and XbaI sites of pLVX-Puro (Clontech Inc., Palo Alto, CA, USA). To produce lentiviral particles coding for expression constructs (GRIM-19) or knockdown constructs (STAT3), HEK-293T cells (3 Â 10 6 ) were transfected with 5 mg of transfer vector (for example, pLVX-Puro-GRIM-19-Myc or pLKO1-sh-STAT3), 3.75 mg of packaging plasmid (pCMVdR8.2 dvpr) and 1.5 mg of envelope plasmid (pVSV-G) (Addgene Inc., Cambridge, MA, USA) using a Lipofectamine-Plus reagent (Invitrogen Inc.) for 6 h in serum-free medium. Cells were then fed with 10 ml of regular growth medium (DMEM (Dulbecco's modified Eagle's medium) with 10% FBS (fetal bovine serum)). The viral particles from the growth medium were collected from 48 to 96 h post transfection. The medium was centrifuged to remove debris, filtered through 0.45 mm filter and centrifuged at 50 000 g for 90 min at 4 1C. The viral particle pellet was suspended in 200 ml TNE buffer (50 mM Tris-Cl pH 7.8, 130 mM NaCl and 1 mM EDTA). Expression or knockdown of the target genes was assessed by performing the western blot analysis with specific antibodies.
Establishment of stable cell lines
A non-oncogenic immortalized rodent fibroblast cell line (3Y1) was employed for clearly defining the anti-v-Src effect of GRIM-19. The 3Y1 and 3Y1/v-Src cells were described in the previous study (Kalakonda et al., 2007a) . 3Y1/GRIM-19 and 3Y1/GRIM-19/v-Src dual expression cells were established by infecting 3Y1 and 3Y1/v-Src cells with GRIM-19 coding lentiviral particles, respectively, and selecting with puromycin (2 mg/ml) for 10-12 days. In the STAT3 knockdown experiment, v-Src-expressing cells were infected with lentiviral particles coding STAT3 shRNA and treated with puromycin (2 mg/ml) for 7 days. All studies were conducted using pools of colonies (n ¼ 75-100) to avoid a clonal bias.
Immunofluorescence microscopy Cells were cultured on a sterile cover glass (Fisher Scientific Inc., Pittsburgh, PA, USA) in a 24-well tissue culture plate for 24 h before staining and fixed for 15 min using 3.7% of paraformaldehyde, permeabilized with 0.5% of Triton X-100 in PBS (phosphate-buffered saline) and blocked in 5% of BSA (bovine serum albumin). Primary and secondary antibodies were diluted in PBS containing 5% of BSA, incubated for 1 h and washed. Hoechst was used to stain nuclei. Direct immunofluorescence was employed to visualize a-tubulin and actin network using FITC-conjugated anti-a-tubulin (1:400) and AlexaFluor555-conjugated phalloidin (1:400), respectively. Indirect immunofluorescence was used to visualize detyrosinated tubulin and GRIM-19 using rabbit antibodies (1:200) and anti-Myc-tag IgG (1:500), respectively, with corresponding fluorescent-labeled secondary antibody listed above. Images were captured using a fluorescence microscope (Olympus BX-FLA, Osaka, Japan) fitted with a digital camera (QICAM, Surrey, British Columbia, Canada) and processed by Q-capture pro 5.1 (Q-Imaging Corporation, Surrey, British Columbia, Canada). Cell counting was performed on captured immunofluorescent images from five randomly selected fields with each field containing B70 cells and subjected to statistical analysis with Student's t-test.
In vitro wound healing assay Cells lines expressing various genes were grown in DMEM with 5% FBS and penicillin-streptomycin in a six-well plate. Confluent monolayers were scratched with a 200 ml pipette tip to make a wound. The monolayer was washed twice with PBS to remove the detached cells, supplemented with full medium and incubated for 4 h at 37 1C. We first marked the injured front and measured space between the injured edges. Images were captured using a Nikon Eclipse TS-100 microscope fitted with a digital camera to monitor the cell movement into the wounded area. All micrographs were taken at the same time at the same magnification. For quantification of wound closure, the width of each wound was measured after 4 h and expressed as a percentage of original wound size as described elsewhere (Scott et al., 2004) . Mean values from six different plates (that is, photomicrographs) per cell line were used for calculating these data.
Metastatic assays
Three-to four-week-old athymic nude (nu/nu) NCr mice (Taconic, Rensselaer, NY, USA) were used for these studies as described earlier (Lindner et al., 1997) . Procedures involving animals and their care were conducted in conformity with an institutionally approved protocol compliant with United States national and international laws and policies. For metastasis experiments, B50 000 cells/mouse were injected through the tail vein. After 7 weeks, animals (n ¼ 10/group) were euthanized and evaluated for lung metastases by performing necropsy. Tumors were found only in the lungs. Student's t-test was used to assess the statistical significance of difference between pairs of mean numbers of tumors formed.
